

## 217

**MECHANISMS OF ACTION OF ESE1, A NOVEL TRANSCRIPTIONAL REGULATOR OF CARTILAGE REMODELING, IN MMP-13 REGULATION**

**E. Olivetto**<sup>1,2</sup>, M. Otero<sup>1</sup>, D.A. Plumb<sup>1</sup>, C. Dragomir<sup>1</sup>, K. Tsuchimochi<sup>3</sup>, R.M. Borzi<sup>2</sup>, A. Facchini<sup>2</sup>, K.B. Marcu<sup>4,2</sup>, M.B. Goldring<sup>1</sup>  
<sup>1</sup>Hosp. for Special Surgery, New York, NY; <sup>2</sup>Istituti Ortopedici Rizzoli, Bologna, Italy; <sup>3</sup>Kagoshima Univ., Kagoshima, Japan; <sup>4</sup>Stony Brook Univ., Stony Brook, NY

**Purpose:** Matrix metalloproteinase (MMP)-13 plays a major role in cartilage degradation. MMP-13 expression and activity are up-regulated in osteoarthritis (OA) cartilage as compared to non-OA cartilage. We previously reported that *ELF3/ESE1* levels are higher in OA cartilage and that ESE-1 transactivates the *MMP13* promoter via a proximal highly conserved ETS binding site. The aim of this study was to better define the mechanism/s and signalling pathways that modulate the ESE-1-driven *MMP13* promoter activation in chondrocytes.

**Methods:** We investigated the contribution of ESE-1 to MMP-13 expression by siRNA knock down (KD) transfection experiments in human primary chondrocytes and real time PCR analysis of MMP-13 expression induced by IL-1 $\beta$ . The response of the *MMP13* promoter to ESE-1 was analyzed in luciferase reporter assays, after co-transfection of immortalized chondrocytes with human *MMP13* promoter constructs and expression vectors encoding ESE-1, p38, JNK, ERK-1, MKK-6, MKK-7, MEK-1 and MKP-1. ESE-1 binding to the *MMP13* promoter was analyzed by chromatin immunoprecipitation (ChIP) assays. IL-1 $\beta$ -induced ESE-1 nuclear translocation was addressed by Western blotting analysis of cytoplasmic and nuclear fractions of human immortalized chondrocytes.

**Results:** Real time PCR analysis revealed a significant reduction of IL-1 $\beta$ -induced MMP-13 mRNA levels associated with ESE-1 KD in human primary chondrocytes. Luciferase reporter assays showed that MEK1/ERK1 overexpression enhanced ESE1-driven activities of the -1528/+27 and -267/+27 *MMP13* promoter constructs, whereas MKK6/p38 or MKK7/JNK overexpression did not affect ESE-1 transactivation of MMP-13. Overexpression of MKP-1 reduced both the ESE-1 activation of *MMP13* and also the MEK1/ERK1 enhancement of ESE-1-driven *MMP13* activation. Accordingly, pre-treatment with the MEK1/2 inhibitor, U0126, decreased the *MMP13* promoter activity induced by ESE-1 overexpression. Finally, Western blotting analysis revealed that IL-1 $\beta$  stimulation induced ESE-1 nuclear translocation, which correlated with increased ESE-1 binding to the endogenous *MMP13* promoter, as addressed by ChIP assays.

**Conclusions:** The role of MMP-13 as a central factor for OA progression has been highlighted by recent studies in *Mmp13* knockout mice. We previously reported that ESE-1 is a key factor in controlling *MMP13* transcription. ESE-1 belongs to the ETS family of transcription factors, which are classic MAPK effectors in different tissues and cell types. Here, we show that ESE-1 participates in the IL-1 $\beta$ -induced MMP-13 expression and that IL-1 $\beta$  induces ESE-1 nuclear translocation and binding to the *MMP13* promoter. In addition, we show that the ESE1-driven transactivation of *MMP13* is enhanced by MEK1/ERK1. In chondrocytes, ERK1/2 phosphorylation is increased *in vitro* in response to IL-1 $\beta$  and *in vivo* in OA cartilage, and MEK/ERK activation has been reported to participate in the cytokine-induced MMP-13 expression. Therefore, ESE-1 could be one of the effectors of the MEK/ERK pathway in controlling MMP-13 expression in chondrocytes, and the relative contributions of the MEK/ERK/ESE1 axis in OA with regard to MMP-13 expression and activity will merit further investigation.

## 218

**TEMPORAL EXPRESSION AND TISSUE DISTRIBUTION OF INTERLEUKIN-1 $\beta$  IN TWO STRAINS OF GUINEA PIGS WITH VARYING DEGREES OF SPONTANEOUS OSTEOARTHRITIS**

**K.S. Santangelo**, G.J. Nuovo, E. Pieczarka, S.E. Weisbrode, A.L. Bertone  
 The Ohio State Univ., Columbus, OH

**Purpose:** Interleukin-1 $\beta$  (IL-1 $\beta$ ) has been cited as a major cytokine involved in OA-related joint degeneration but definitive characterization of its role *in vivo* remains elusive. The objective of this study was to determine the temporal expression and tissue distribution of IL-1 $\beta$  in whole knee joints harvested from OA-prone and resistant guinea pigs via immunohistochemistry (IHC). Two main hypotheses were tested: 1) differences in IL-1 $\beta$  expression would be detected in joint tissue of OA-prone animals

during the course of disease progression; and 2) IL-1 $\beta$  expression patterns in OA-prone animals would differ from that of OA-resistant animals.

**Methods:** OA-prone Hartley (N=24) and OA-resistant Strain 13 (N=24) guinea pigs were collected at 60, 120, 180, 240, 360, and 480 days of age (N=4 per strain per time point). IHC was performed on paraffin-embedded sections of whole knee joints and the distribution of IL-1 $\beta$  expression in all tissue was both descriptively described and scored. OA was graded on toluidine blue stained coronal sections using Mankin criteria with modifications specific for the guinea pig. Data was reported as median and range, and statistical analysis was performed using the Kruskal-Wallis one-way analysis of variance by ranks followed by Dunn's post test.

**Results:** Median OA scores for both strains increased from 60 to 480 days of age, and a statistically higher score (p<0.01) was found in Hartley animals by 480 days of age. The tissue distribution and intensity of IL-1 $\beta$  immunostaining was consistent within the knee joint organs for each group (strain and age) examined, allowing identification of differing expression patterns in cartilage, synovium, menisci, and subchondral bone both within and between guinea pig models over time. The most striking finding was persistent IL-1 $\beta$  expression in all aforementioned tissues in Hartley guinea pigs at 120 and 180 days of age, while Strain 13 animals demonstrated a significant (p<0.05) and marked reduction in positive cells and/or matrix at these same time points. Further, when present, the distribution of positive protein detection often varied within tissue type for each guinea pig strain. For example, descriptive regional differences in weight-bearing cartilage were discerned between guinea pig strains at 360 and 480 days of age. Immunostaining in the cartilage of Hartley guinea pigs at these time points was restricted to midline and medial or lateral regions, while positive cells and/or matrix of Strain 13 animals were present only in central regions.

**Conclusions:** This study provides evidence that IL-1 $\beta$  continues to be an important biomarker relevant to the development and progression of OA. Although these findings do not directly explicate a cause-and-effect relationship between IL-1 $\beta$  and OA, data is provided as to a window of time when targeted cytokine reduction and/or blockade may prove effective in elucidating such a correlation and identifying its mechanistic components. In this vein, *in vitro* and *in vivo* investigations are underway to determine the effects that reduction of IL-1 $\beta$  via RNA interference may have on other key mediators implicated in OA. Alternately, should IL-1 $\beta$ , itself, prove to represent only a secondary response to a more primary insult propagating OA pathogenesis, groundwork has been laid to hone in on the offending pathway.

## 219

**THE COMBINATION OF IL-4 AND IL-10 PROTECTS AGAINST BLOOD-INDUCED CARTILAGE DAMAGE**

**M.E. van Meegeren**<sup>1,2</sup>, S.C. Mastbergen<sup>1</sup>, N.W. Jansen<sup>1,2</sup>, G. Roosendaal<sup>2</sup>, F.P. Lafeber<sup>1</sup>

<sup>1</sup>Rheumatology & Clinical Immunology, Univ. Med. Ctr. Utrecht, Utrecht, Netherlands; <sup>2</sup>Haematology and Van Creveld Clinic, Univ. Med. Ctr. Utrecht, Utrecht, Netherlands

**Purpose:** Exposure of cartilage to blood can occur after joint trauma, during or after major joint surgery, or in hemophilia patients. This ultimately leads to joint damage, having both the inflammatory characteristics of rheumatoid arthritis and the degenerative characteristics of osteoarthritis. It was shown that *in vitro* exposure of cartilage to 50% v/v blood for 4 days, the supposed natural evacuation time of blood from a joint, leads to 98% inhibition of cartilage matrix synthesis. Even after a recovery period of 12 days (in the absence of blood) cartilage matrix synthesis is still inhibited by 78%. We have previously demonstrated that interleukin (IL)-10 limits *in vitro* blood-induced cartilage damage. In addition, IL-4 has been suggested to have cartilage protective properties. Hence our aim was to study whether IL-4 can support IL-10 in the prevention of blood-induced cartilage damage.

**Methods:** Human full thickness articular cartilage explants were cultured for 4 days in the presence or absence of 50% v/v homologous blood. IL-4 was added in concentrations of 0, 1, 3, 10, 30, or 100 ng/ml during blood exposure. A combination of IL-4 and IL-10 was added in a concentration of 100 ng/ml. After 4 days the medium was refreshed and cartilage was cultured for an additional 12 days in the absence of additives to determine long-term effects of short-term blood-exposure and treatment. Cartilage matrix turnover, in terms of proteoglycan synthesis, -release, and -content, was determined at day 16.